Steve Greenberg, MD, PhD
Dr. Greenberg has authored over 280 research articles in the areas of hemorrhagic stroke and small vessel brain disease. He has served in many national and international leadership roles in the fields of stroke and neurology including President of the International CAA Association, co-chair of a NINDS Alzheimer’s Disease-Related Dementias Summit subcommittee, and chair of the American Heart Association International Stroke Conference. Dr. Greenberg is the current Principal Investigator for several active research studies investigating CAA.
Edip Gurol, MD, MSc
Dr. Gurol is a stroke neurologist with expertise in the care of patients at high risk for strokes. His NIH-funded research focuses on clarifying the mechanisms of brain small vessel diseases that increase stroke risk. Dr. Gurol is PI of multiple research studies actively enrolling patients with CAA, cerebral small vessel disease and/or hemorrhagic stroke.
Mariel Kozberg, MD, PhD
Dr. Kozberg is a vascular neurologist whose research focuses on understanding mechanisms of intracerebral hemorrhage in CAA. She uses a range of state-of-the art imaging systems to examine vascular pathophysiology, blood-brain barrier disruption, and brain inflammation in CAA with the goal of identifying new biomarkers and therapeutic targets.
Valentina Perosa, MD, PhD
Dr. Perosa is an investigator with a clinical background in Neurology. Her main research goal is to better understand the mechanisms linking cerebral amyloid angiopathy (CAA), arteriolosclerosis, and Alzheimer’s disease (AD) in order to identify novel therapeutic targets. To achieve this, she employs a combination of methods, ranging from advanced in vivo and ex vivo neuroimaging to deep-learning-based quantitative neuropathology.
Susanne Van Veluw, PhD
Dr. Van Veluw is the director of the translational CAA research lab and the co-coordinator of the Leducq Foundation transatlantic network of excellence on brain clearance. Members of her lab focus on unraveling the pathophysiological mechanisms of microvascular injury in cerebral amyloid angiopathy (CAA). They use a combination of in vivo MRI, ex vivo MRI-guided neuropathological examination in human brain tissue, and in vivo optical microscopy in mouse models, in the hope to identify novel targets for much needed early intervention strategies.
Anand Viswanathan, MD, PhD
Dr. Viswanathan is a member of the Massachusetts Alzheimer's Disease Research Center and is a staff neurologist in both the Stroke Service and Memory Disorders Unit. Dr. Viswanathan's research interests include studying the contributions of stroke and vascular risk factors to dementia. He serves as Principal Investigator for several active projects enrolling patients with CAA and other forms of cerebral small vessel disease.